The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring.
Adherence
Contraceptive vaginal ring
Pharmacokinetic
Segesterone acetate
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
06
08
2021
revised:
23
11
2021
accepted:
08
12
2021
pubmed:
1
1
2022
medline:
23
4
2022
entrez:
31
12
2021
Statut:
ppublish
Résumé
To determine the incidence of out-of-range segesterone acetate (NES) concentrations in participants of a pharmacokinetic/pharmacodynamic trial of a continuous use contraceptive vaginal ring (CVR) releasing NES and estradiol (E2). We hypothesized that out-of-range concentrations reflect nonadherent ring use and predict ovulation risk. We conducted a secondary analysis of data from a prospective, multi-centered, randomized, Phase IIa dose-finding trial for a CVR releasing NES and E2. Our primary outcome was the risk of ovulation associated with out-of-range NES events. We calculated the 5th and 95th percentile NES concentrations of subjects at steady state to determine high and low cutoffs. We used a Fisher's exact test to determine group differences, and calculated the relative risk of ovulation for each group. We analyzed available serum NES data from cycles 2 (n = 172), 3 (n = 156) and 7 (n = 115) to determine the 5th and 95th percentile of all NES concentrations (64, 296 pg/mL). In the 443 cycles of observation, no ovulations occurred in participants with NES concentrations within the expected range. In contrast, we found ovulatory elevations of progesterone in 21 cycles with out-of-range values. Of these, 15 (71%) cycles had evidence of one or more nonadherent low and 6 (29%) one or more unexpected peak. The relative risk of ovulation increased with evidence of multiple non-adherent levels. We found out-of-range NES concentrations, suggestive of improper use of a CVR associated with an increased risk of ovulation, with a direct relationship between the number of out-of-range events and the relative risk. The results of this study support the use of out-of-range serum NES values as a marker of adherence in contraceptive clinical trials of continuous vaginal rings, and suggest that nonadherence occurs even in early phase clinical trials with close monitoring.
Identifiants
pubmed: 34971614
pii: S0010-7824(21)00477-7
doi: 10.1016/j.contraception.2021.12.004
pii:
doi:
Substances chimiques
Contraceptive Agents
0
Contraceptive Agents, Female
0
Drug Combinations
0
Norprogesterones
0
Pregnenediones
0
segesterone acetate and ethinyl estradiol vaginal system
0
Ethinyl Estradiol
423D2T571U
Progesterone
4G7DS2Q64Y
Estradiol
4TI98Z838E
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-64Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201200008I
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.